Welcome to our dedicated page for Angiodynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamics stock.
Overview
AngioDynamics Inc is a Nasdaq-listed public company renowned for designing, manufacturing, and selling a broad portfolio of innovative medical devices that serve diverse clinical applications. With deep expertise in the fields of oncology, interventional radiology, and vascular surgery, the company focuses on the minimally invasive treatment of diseases such as peripheral vascular disorders and cancer. Industry-specific keywords such as "minimally invasive procedures", "diagnostic devices", and "interventional radiology" underscore the company’s commitment to technological innovation.
Core Business and Operations
The company operates by providing a comprehensive range of devices which include systems for radiofrequency ablation, vascular access, angiographic procedures, dialysis support, angioplasty, drainage, thrombolysis, embolization, and venous treatments. These products are designed for use in clinical settings by interventional radiologists, surgeons, and nephrologists. Through its diverse product line, AngioDynamics is able to offer end-to-end solutions that enhance procedural efficiency and patient outcomes. The revenue model primarily relies on direct sales to healthcare institutions, supported by a strong service network ensuring reliability and continued product support.
Market Position and Competitive Landscape
AngioDynamics has distinguished itself in a technologically competitive and high-growth industry. By investing in research and development, the company has maintained its ability to continuously bring forward new technologies and improve existing products. This commitment to innovation positions the company among notable competitors in the medical device industry. Its competitive differentiation stems from a consistent track record of product innovation, robust clinical performance, and strategic market presence. The company's market position is further bolstered by its focused approach to addressing specialized clinical needs and its ability to integrate advanced technological solutions into traditional treatment paradigms.
Product Portfolio and Technological Innovation
The product portfolio of AngioDynamics spans a wide range of medical device categories. From advanced radiofrequency ablation systems to precision surgical tools, the company leverages cutting-edge technology to develop devices that offer improved safety profiles and enhanced procedural outcomes. Emphasis on 'innovative technology' and 'minimally invasive procedures' highlights the company’s pursuit of excellence in device performance. Each product category is built on comprehensive clinical insights and a deep understanding of procedural requirements, ensuring that healthcare providers are equipped with devices that cater to their diagnostic and therapeutic needs.
Operational Excellence and Industry Expertise
AngioDynamics demonstrates operational excellence by aligning its product development with the evolving needs of healthcare providers. The company’s strategic focus on clinical innovation and rigorous quality control reflects its deep industry expertise and commitment to delivering reliable and effective medical solutions. Structured research programs, continuous product improvements, and a robust post-market support system underpin the company’s reputation for innovation and operational excellence. This integrated approach assists healthcare professionals in achieving improved outcomes while ensuring safety and compliance under constantly evolving medical standards.
Strategic Business Model and Value Proposition
Central to AngioDynamics' value proposition is the delivery of solutions that advance the standard of care in critical clinical procedures. The company’s business model is built around the continuous enhancement of product performance and the facilitation of minimally invasive therapeutic options. By maintaining a deep focus on quality and usability, AngioDynamics provides a reliable partnership for medical institutions seeking to integrate innovative device technologies. This strategic alignment with frontline clinical needs makes the company a noteworthy reference point for discussions on medical innovation, procedural efficiency, and enhanced patient care.
Industry Impact and Long-Term Relevance
With a rich history dating back to its founding in 1988, AngioDynamics has consistently contributed to medical advancements through its innovative product solutions. The company's impact on the healthcare industry is visible across multiple clinical areas, reinforcing its role as a significant player in medical technology. The enduring relevance of its products and the clarity of its market focus ensures that AngioDynamics remains a principal component in the discussion of medical device innovation and procedural technology. This comprehensive approach, combined with clear communication and expert-driven design, continues to shape the narrative around modern, efficient, and effective clinical practices.
AngioDynamics (NASDAQ: ANGO) announced the enrollment of the first patient in the APEX-AV Study, evaluating the AlphaVac MMA F1885 System for treating acute intermediate-risk pulmonary embolism (PE). Conducted at 20 U.S. hospital sites, the study aims to assess the device's efficacy and safety. Key endpoints include RV/LV ratio reduction and the rate of major adverse events within 48 hours. This trial, in partnership with The PERT Consortium and Viz.ai, aims to improve PE care using advanced AI recruitment strategies.
AngioDynamics, a medical technology company, reported net sales of $81.5 million for the first quarter of fiscal 2023, marking a 5.9% increase from the prior year. Med Tech sales rose by 29.6% to $22.8 million, driven by solid performances from the Auryon and thrombectomy platforms. However, Med Device sales declined by 1.1% to $58.7 million. The company experienced a gross margin decrease to 51.9% and reported a net loss of $13.0 million or $0.33 per share. Fiscal year 2023 guidance is reaffirmed, expecting net sales between $342 million and $348 million.
AngioDynamics, Inc. (NASDAQ: ANGO) will report its first quarter fiscal year 2023 financial results on October 6, 2022, before market open. Management will host a conference call at 8:00 a.m. ET the same day to discuss the results. Investors can join the conference call by dialing 1-877-407-0784 (domestic) or +1-201-689-8560 (international), using passcode 13732702. The call will be webcast on AngioDynamics' website, with a replay available shortly after the call.
AngioDynamics, Inc. (NASDAQ: ANGO) announced that Executive Vice President and CFO, Stephen Trowbridge, will present at the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, at 2:00 p.m. ET. Investors can access a live webcast of the presentation on AngioDynamics' website, with a replay available afterward. The company focuses on innovative medical technologies aimed at restoring blood flow, enhancing cancer treatment options, and improving patient quality of life. More information is available at www.angiodynamics.com.
AngioDynamics, Inc. (NASDAQ: ANGO) reported its fourth quarter and fiscal year 2022 results, highlighting a 13.2% increase in net sales, totaling $87.0 million. However, gross margin decreased to 53.4%, down 170 basis points year-over-year. The company posted a GAAP loss per share of $0.16 for the quarter. For the full year, net sales reached $316.2 million, with a 8.7% increase over the previous year, but also a GAAP loss per share of $0.68. Looking ahead, AngioDynamics anticipates fiscal year 2023 net sales between $342 million and $348 million.
AngioDynamics, Inc. (NASDAQ: ANGO) will release its financial results for Q4 and fiscal year 2022 on July 12, 2022, before market open. A conference call is scheduled for 8:00 a.m. ET on the same day to discuss the results. Investors can join via phone or through a webcast available on AngioDynamics' website. A recording of the call will be accessible from 11:00 a.m. ET on July 12 until 11:59 p.m. ET on July 19. The company focuses on innovative medical technologies aimed at improving vascular health and cancer treatment.
AngioDynamics, Inc. (NASDAQ: ANGO) announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the UBS Global Healthcare Conference on May 23, 2022, at 4:15 p.m. ET. The presentation will focus on the company's innovations in medical technology aimed at restoring blood flow, enhancing cancer treatments, and improving patient quality of life. A live webcast will be available on the company’s website, with replay options following the event. AngioDynamics is recognized for addressing critical healthcare needs with its advanced technologies.
AngioDynamics, Inc. (NASDAQ: ANGO), a leader in medical technology, announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the BofA Securities Healthcare Conference on May 10, 2022, at 10:00 a.m. PT (1:00 p.m. ET). The presentation can be viewed via live webcast on the company’s website and will be available for replay afterward. AngioDynamics specializes in restoring blood flow, expanding cancer treatment options, and enhancing patient quality of life through innovative healthcare solutions.
AngioDynamics reported a net sales increase of 3.9% to $74.0 million in Q3 fiscal 2022. Med Tech sales soared 28.6%, but Med Device saw a 2.8% decline. The gross margin decreased by 190 basis points to 52.2%. The company posted a GAAP loss per share of $0.13, though adjusted EPS rose to $0.03. Key FDA approvals were achieved for AlphaVac F18, and the company initiated the PRESERVE study. Despite challenges from COVID and inflation, AngioDynamics remains optimistic about long-term growth, projecting FY2022 net sales between $310 and $315 million.
AngioDynamics, a medical technology leader, will present at the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 2:15 p.m. ET. Jim Clemmer, President and CEO, and Stephen Trowbridge, CFO, will represent the company. A live webcast of the presentation will be available on AngioDynamics' website, with a replay accessible post-event. The company specializes in technologies aimed at restoring healthy blood flow and improving patient quality of life, catering to unmet medical needs.
FAQ
What is the current stock price of Angiodynamics (ANGO)?
What is the market cap of Angiodynamics (ANGO)?
What does AngioDynamics specialize in?
How does AngioDynamics generate its revenue?
What are the key product categories offered by AngioDynamics?
How does AngioDynamics differentiate itself from competitors?
Who are the primary customers of AngioDynamics?
What is the significance of minimally invasive procedures in their product development?
How does the company maintain its industry expertise?
What role does innovation play in AngioDynamics' business model?
